PI3Kα inhibitors that inhibit metastasis. - Wikidata - wikimedia - TriplyDB

PI3Kα inhibitors that inhibit metastasis.

PI3Kα inhibitors that inhibit metastasis.

http://www.wikidata.org/entity/Q34416746

about

Rapalogs in cancer prevention: anti-aging or anticancer?GSK-3 as potential target for therapeutic intervention in cancer MicroRNA expression characterizes oligometastasis(es)Advances in targeting signal transduction pathways Wnt5a and CCL25 promote adult T-cell acute lymphoblastic leukemia cell migration, invasion and metastasis.WNT signaling and distant metastasis in colon cancer through transcriptional activity of nuclear β-Catenin depend on active PI3K signaling.PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells.The structural basis for cancer treatment decisions.Selective anti-cancer agents as anti-aging drugs Activation of diverse signalling pathways by oncogenic PIK3CA mutations.Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer.mTOR inhibition elicits a dramatic response in PI3K-dependent colon cancers.A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types Thiazolidinedione-based PI3Kα inhibitors: an analysis of biochemical and virtual screening methods.Hormesis does not make sense except in the light of TOR-driven aging.Molecular damage in cancer: an argument for mTOR-driven aging NCI's provocative questions on cancer: some answers to ignite discussion.Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog-like gerosuppression?Definition of the binding mode of a new class of phosphoinositide 3-kinase α-selective inhibitors using in vitro mutagenesis of non-conserved amino acids and kinetic analysis.Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine Answering the ultimate question "what is the proximal cause of aging?"Recent discoveries in the cycling, growing and aging of the p53 field Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging.Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions.Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells.P3Kα: a driver of tumor metastasis?Virosecurinine induces apoptosis in human leukemia THP-1 cells and other underlying molecular mechanisms.

P2860

Q26866151-62C95C2D-3A3B-4C21-9060-1C130C5CF4DB Q27013811-999320A0-3764-43EE-8E98-36DD2DDC716B Q27311314-B97BE204-4D9B-4048-9703-ED3743850624 Q27686983-0C9E9D49-663A-43AD-838B-C8DB0A6AA57D Q33889070-CE0930B2-67E6-49FB-A59E-602A127C0A3C Q33917543-2A86B83C-6F2B-4562-BE8E-13E029262F39 Q33987852-B8A3434D-A36C-4355-AF80-F836FBD31F8C Q34060558-09E0727D-F027-4BE7-ADD1-10D0484D4C54 Q34365654-0C1AFE23-CCE6-4502-B968-EBB46518F92A Q34392470-72699A23-6384-431F-B75A-9DE013FC9A63 Q34408364-7C655E13-E87E-40A2-9359-640F7C9F8E0C Q34530885-61C7BEA1-E720-4D49-9D34-835523015394 Q34673900-9D3BFEE4-98DC-439E-848B-AA52F6AE039B Q35215580-A8E4E36D-BB9E-412E-9F4D-5D627CA942C5 Q35276540-C00F7533-11CE-48F0-BCEF-024F91532423 Q35645142-61F194F6-B701-42E2-B65F-203D0437B546 Q35740772-9264A799-6CA8-4493-B19F-7A01DEE5DF7E Q35764401-4047B7D0-1641-4362-BDA2-BDC11FC6455A Q36209128-B99436AE-8EB5-4C8D-AFD8-BF4C71627962 Q36327175-0E29C204-7EF5-45EF-9D49-985D27AA5601 Q36339232-EBB5CC2A-BF6C-48FA-85AA-F436261B2692 Q36556350-D3F3CBBA-D926-4CEF-8505-15732BF4CDA4 Q36736351-1C652844-1D9E-4163-9E54-6F1ABF3A1FA2 Q36736358-0E83667A-36A3-4D4A-9832-2CE31249A6BB Q36736362-029F33A3-741C-4CF6-916E-A8BD261AC7B6 Q36926148-38EFF52B-950B-4EA6-9FAA-4D5368BC0557 Q39446680-FEDECD3E-529E-4675-A150-38005DB846CA Q42751622-1E69BC10-FABD-45B5-B6EF-E3352976F297 Q49335200-412068ED-C76E-425B-9998-4867576F8D32

P2860

PI3Kα inhibitors that inhibit metastasis.

http://www.wikidata.org/entity/Q34416746

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

PI3Kα inhibitors that inhibit metastasis.

@ast

PI3Kα inhibitors that inhibit metastasis.

@en

PI3Kα inhibitors that inhibit metastasis.

@nl

type

label

PI3Kα inhibitors that inhibit metastasis.

@ast

PI3Kα inhibitors that inhibit metastasis.

@en

PI3Kα inhibitors that inhibit metastasis.

@nl

prefLabel

PI3Kα inhibitors that inhibit metastasis.

@ast

PI3Kα inhibitors that inhibit metastasis.

@en

PI3Kα inhibitors that inhibit metastasis.

@nl

P1433

Q34416746-731B5B41-95B1-47ED-9EC1-FC9D82127841

P1476

Q34416746-AD4444CA-6E37-4217-A0A6-EE0148A9FF32

P2093

Q34416746-28D73AF5-A575-442E-AA9C-79E02C718CEC

Q34416746-3553F6EE-CE93-4B3C-A1AF-E125EF794571

Q34416746-55690450-A9F3-472D-A3CE-1A8246917406

Q34416746-ADE32D9A-24AB-43D0-B55F-C23E00631049

Q34416746-BC8CEB5C-316B-4F85-BEB8-6BD28EDBDB73

Q34416746-C4EAB1E7-1C8C-4D76-A7F2-7D73176C9AFE

Q34416746-D0ACBD4E-BA29-4CE8-AC32-F4757CBB6106

Q34416746-F6A7211A-0B0A-4678-B504-D879099CCFFE

Q34416746-FB4CD885-4525-4B5F-889F-CFA40A5C5F70

P2860

Q34416746-0A694C0F-BE28-41CA-9C78-9C793EC40FF7

Q34416746-12F4FC80-5110-4CD8-AB18-7B696AD7CA6D

Q34416746-201C3916-9B39-47AE-BFFC-44883A9B8BF1

Q34416746-26163679-54B0-4728-BCD1-F66503A223B8

Q34416746-27F3EDA2-A85B-4F62-9658-B8670BF56CCB

Q34416746-288826FA-4594-44B2-B4EF-5AB3D221B4CB

Q34416746-411DEBC1-3EEA-4321-817B-867987B40B9C

Q34416746-4D3CED79-96BF-4634-BF66-841D6F7904CA

Q34416746-5196E226-0CE8-4B07-9ACA-716A914EADD8

Q34416746-55F3112C-C734-4F2F-8A04-F7B79389D6E1

P304

Q34416746-D86938A4-D366-4BA0-92CA-4F54DA0F3E16

P31

Q34416746-F5CFFA29-1488-4ABC-B725-5E22FF1A8C6E

P356

Q34416746-338CE323-B4CD-4B83-B34C-067D59DB9AC6

P407

Q34416746-3FF40ED8-CBC1-4DCD-B951-58A84919EC79

P433

Q34416746-7D4DE5EA-554E-45DB-9273-77B18A464265

P478

Q34416746-153AF1E0-695F-44B5-9D32-57745297BEE2

P50

Q34416746-29803EE0-9FDA-48C9-91F7-A00EB936F55E

Q34416746-E3D9A8B6-B47F-452F-B62A-9280F13F2C41

P577

Q34416746-F75D6318-66D6-40A1-BFBE-ADFA6AA32AFD

P5875

Q34416746-DB69D628-07DE-4147-BB2B-75CFC3CED2E7

P698

Q34416746-D837FD46-8157-4DA2-B29B-D525BCADA3E0

P932

Q34416746-1F8594FE-CFEB-45BC-9674-2F7D40828541

P356

P1433

P1476

PI3Kα inhibitors that inhibit metastasis.

@en

P2093

Christoph Lengauer

http://www.w3.org/2001/XMLSchema#string

David L Huso

http://www.w3.org/2001/XMLSchema#string

Guosheng Liu

http://www.w3.org/2001/XMLSchema#string

Jian Yang

http://www.w3.org/2001/XMLSchema#string

Jiuxiang Zhu

http://www.w3.org/2001/XMLSchema#string

Oleg Schmidt-Kittler

http://www.w3.org/2001/XMLSchema#string

Sandra B Gabelli

http://www.w3.org/2001/XMLSchema#string

Shibin Zhou

http://www.w3.org/2001/XMLSchema#string

William Hendricks

http://www.w3.org/2001/XMLSchema#string

P2860

First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting

A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling

The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations

A frequent kinase domain mutation that changes the interaction between PI3K and the membrane

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

High frequency of mutations of the PIK3CA gene in human cancers

Signaling by distinct classes of phosphoinositide 3-kinases

Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

P304

339-348

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.166

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth W Kinzler

Bert Vogelstein

P577

2010-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49703378

http://www.w3.org/2001/XMLSchema#string

P698

21179398

http://www.w3.org/2001/XMLSchema#string

P932

3004370

http://www.w3.org/2001/XMLSchema#string